Amryt Pharma plc reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 61.13 million compared to USD 56.52 million a year ago. Net loss was USD 20.8 million compared to USD 17.21 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.35 a year ago. Diluted loss per share from continuing operations was USD 0.3 compared to USD 0.35 a year ago.
For the nine months, sales was USD 188.79 million compared to USD 167.71 million a year ago. Net loss was USD 42.34 million compared to USD 40.55 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 1 a year ago. Diluted loss per share from continuing operations was USD 0.65 compared to USD 1 a year ago.